One of the promising painkillers, buprenorphine, being a partial MOR agonist and KOR antagonist, is recommended alone, or in combination with naloxone, in opioid-naïve cancer patients for treatment of chronic and stable pain. This evidence concerns the gene OPRK1 and cancer.